Ano5 Mutation Leads to Bone Dysfunction of Gnathodiaphyseal Dysplasia via Disturbing Akt Signaling

doi:10.21203/rs.3.rs-4897322/v1

Download PDF

Research Article

Ano5 Mutation Leads to Bone Dysfunction of Gnathodiaphyseal Dysplasia via Disturbing Akt Signaling

https://doi.org/10.21203/rs.3.rs-4897322/v1

This work is licensed under a CC BY 4.0 License

You are reading this latest preprint version

Background

Gnathodiaphyseal dysplasia (GDD) is a rare autosomal dominant genetic disease characterized by osteosclerosis of the tubular bones and cemento-osseous lesions of the mandibles. Anoctamin 5 (ANO5) is the pathogenic gene, however, the specific molecular mechanism of GDD remains unclear. Herein, a knockin (Ano5^KI/KI) mouse model expressing the human mutation p.Cys360Tyr was used to investigate the role of Akt signaling in enhanced osteogenesis and decreased osteoclastogenesis in GDD.

Methods

Bone marrow-derived macrophages (BMMs) and mouse calvarial osteoblasts (mCOBs) were isolated from homozygous Ano5^KI/KI mice and treated with SC79, a specific Akt activator. The differentiation and F-actin ring formation of osteoclasts were examined by TRAP and phalloidin staining, respectively. Osteoblast differentiation and mineralization were examined by ALP and alizarin red staining. The expression of bone remodeling-related factors was measured by qRT-PCR.

Results

Akt activation promoted the generation of TRAP-positive multinucleated osteoclasts and the formation of actin rings in Ano5^KI/KI BMMs cultures, accompanied by increased expression of Nfatc1, Trap, Dc-stamp, Mmp9, Ctsk, and Atp6v0d2. Additionally, Ano5^Cys360Tyr mutation down-regulated the Akt phosphorylation level in osteoblast. ALP activity and matrix mineralization capacity in Ano5^KI/KI osteoblast cultures were inhibited after SC79 stimulation, with reduced expression of Runx2, Opn, Col1a1, and Ocn.

Conclusion

Akt activation by SC79 stimulation can obviously rescue abnormal increased osteogenesis and decreased osteoclastogenesis in Ano5^KI/KI mouse model, which demonstrated that disturbed Akt signaling pathway may play a pivotal role in the pathogenesis of GDD, and an Akt activator is probable a therapeutic target for GDD.

Ano5

GDD

Akt

Osteoblast

Osteoclast

Gnathodiaphyseal dysplasia (GDD; OMIM: 166260) is a rare skeletal syndrome characterized by sclerosis of limb bones and cemento-osseous lesions in mandibles that occurs in an autosomal dominant pattern [1]. Anoctamin 5 (ANO5; TMEM16E), encoding a 913 amino-acid protein belonging to the TMEM16 family, was mapped in chromosome 11p14.3–15.1 by linkage analysis and identified to cause GDD [2, 3]. Recessive mutations in the ANO5 gene cause two types of muscular dystrophies, proximal limb-girdle muscular dystrophy type 2 (LGMD2L) and Miyoshi muscular dystrophy 3 (MMD3) [4]. Although ANO5 is involved in various disorders, little is known about the molecular function of the ANO5 protein. Considering that ANO5 is located in the endoplasmic reticulum or cell membrane [5, 6], several lines of evidence have manifested that ANO5 functions as a calcium-activated chloride channels (CaCCs) or phospholipid scrambling protein.

Heretofore, few preliminary studies on the role of ANO5 in bone remodeling have been performed. Research has shown that ANO5 does not affect osteoblast differentiation and mineralization [7]; on the other hand, XJ Qin demonstrated that Ano5-deficient mice exhibited suppressed osteogenesis due to abnormal calcium oscillation, which is divergent from the GDD phenotype [8]. In fact, most GDD patients are clinically characterized by elevated serum alkaline phosphatase (ALP) levels, a classical measurement of systematic osteogenic activity, and increased bone mineral density (BMD), as determined by radiographic examinations [9–11]. However, a consensus is emerging about the association between ANO5 and osteoclastogenesis. Ano5 knockdown leads to decreased osteoclast differentiation, and its overexpression consistently promotes osteoclast maturation through Akt/nuclear factor of activated T cells 1 (Nfatc1) signaling pathway [7, 8].

The serine/threonine kinase AKT is located downstream of PI3K and undergoes dual activation in the structural domain, which is phosphorylated by phosphoinositide-dependent kinase-1 (PDK1), and the regulatory domain is phosphorylated by mammalian target of rapamycin complex 2 (mTORC2) [12, 13]. Subsequently, AKT detaches from the cell membrane to regulate downstream signaling molecules, including GSK3β, Akt1/forkhead box class O (FoxO), and mTORC1, which are generally involved in various biological processes, including cell proliferation, survival, protein synthesis, and metabolism [14]. Notably, the modulatory role of Akt signaling in bone homeostasis has drawn substantial concern. Activation of Akt signaling plays a crucial role in enhancing preosteoblast proliferation, initiating osteogenic differentiation, and promoting the maturation of committed osteoblasts, which is essential for bone morphogenetic protein 2 regulatory function for bone remodeling. [15, 16]. As a consequence, Akt1 deficiency in mice leads to osteopenia due to the dysregulation of both osteoblasts and osteoclasts [17]. Furthermore, Akt signaling exerts positive effects on osteoclast differentiation and maturation mediated by increased phosphorylation of GSK3β and nuclear localization of NFATc1 [18].

In our previous study, Ano5^Cys360Tyr knockin (Ano5^KI/KI) mice equivalent to the p.Cys360Tyr mutation in a Han GDD family that was firstly reported by our group was successfully generated and partially replicated GDD phenotypes characterized by enhanced osteoblast differentiation and bone formation. Additionally, mice displayed inhibited osteoclastogenesis, which was closely related with early signaling pathways regulated by RANKL-RANK-TNF receptor associated factor 6 (TRAF6) cascades, including Akt, NF-κB, p38, and Erk signaling [19]. It is worth noting that the phosphorylation of Akt, a classical molecule associated with bone metabolism, was extremely reduced. In the present study, we investigated the effects of the specific Akt activator SC79 on osteoblastogenesis and osteoclastogenesis of mouse calvarial osteoblasts (mCOBs) and bone marrow-derived macrophages (BMMs) from Ano5^KI/KI mice and surmised that Akt signaling pathway plays a crucial role in skeletal dysfunction of GDD.

2.1 Generation of Ano5^KI/KI mice

Adequate measures were taken to minimize pain and discomfort. All protocols were approved by the Institutional Animal Care and Use Committee of the Beijing Stomatological Hospital (approval number: KQYY-202012-005). Ano5^KI/KI mice carrying the p.Cys360Tyr mutation were established through CRISPR Cas9 genomic editing technology. Specifics about the generation and genotype identification of the Ano5 knock-in mouse model were previously described [19]. DNA was extracted from mouse tails according to the instructions of a universal genomic DNA kit (CW2298, CWbio, Jiangsu, China), and then genotyping was performed by polymerase chain reaction (PCR). Mice were housed in a pathogen-free environment under a 12-hour light-dark cycle and fed standard food ad libitum.

2.2 Isolation and culture of mouse osteoclasts

Wild type and Ano5^KI/KI male mice of 6–8 weeks old were sacrificed and their tibias and femurs were collected in PBS. Bone marrow was flushed with alpha-modified minimum essential medium (α-MEM) (12561056, Gibco-Invitrogen, New York, USA) containing 10% fetal bovine serum (10091148, FBS; New York, Gibco, USA) and incubated at 37℃ with 5% CO₂ for 1 day. Nonadherent cells were collected and resuspended in α-MEM supplemented with 30 ng/ml macrophage-colony stimulation factor (31502, M-CSF; PeproTech, Rocky Hill, USA) to promote BMMs proliferation for 3 days. Subsequently, BMMs differentiated and matured under the stimulation of osteoclast differentiation medium consisting of α-MEM supplemented with 30 ng/ml M-CSF and 100 ng/ml receptor activator of nuclear factor-κβ (RANK) ligand (31511C, RANKL; PeproTech, Rocky Hill, USA). The medium was replaced every other day until the formation of mature multinucleated osteoclasts at day 7. 5 µg/ml AKT activator SC79 (S7863, Selleck, Texas, USA) was treated during the entire differentiation time.

2.3 In vitro osteoclastogenesis assay

To identify mature osteoclasts, BMMs were planked in 96-well plates at a density of 5000 cells/well and cultured with osteoclast differentiation medium for 7 days. Next, the cells were washed with phosphate-buffered saline (PBS) (61231114, Gibco, New York, USA) and fixed in 4% paraformaldehyde (DF0135, Leagene, Beijing, China) for 20 min. TRAP staining was performed according to the manufacturer's instructions (387A, Sigma Aldrich, New York, USA). Methyl green staining solution is used to stain the nucleus (G1652, Solarbio, Beijing, China). TRAP-positive multinucleated osteoclasts were observed by microcopy (Olympus BX51, Tokyo, Japan). BMMs were also seeded in 24-well plates at a density of 5×10⁴ cells/well for phalloidin staining as previously reported. After culture period, the cells were incubated with phalloidin-iFluor 488 (ab176753, Abcam, Cambridge, UK) for 40 min and then with DAPI solution (C0065, Solarbio, Beijing, China) for 5 min to perform nuclear staining. F-actin rings were captured under a fluorescence microscope at Ex/Em = 493/517 nm.

2.4 Preparation of mouse calvarial osteoblasts (mCOBs) culture

mCOBs were isolated from postnatal 1- to 3-day-old female and male littermates as previously described [20]. The calvaria were digested in an enzyme mixture containing 2 mg/ml type I collagenase and 0.25% trypsin for four cycles of 15 min/cycle. Then, the cells were harvested and cultured in α-MEM with 10% FBS. For osteogenic induction, mCOBs were then cultured in α-MEM supplemented with 10% FBS, 1% streptomycin/penicillin (15140122, Gibco, New York, USA), 4 µg/ml dexamethasone, 50 mg/ml ascorbic acid and 4 mM β-glycerophosphate (D4902, A5960, and G9422, Sigma-Aldrich, St. Louis, USA). The cultures were changed every two days. 5 µg/ml SC79 was treated during the entire differentiation time. mCOBs were cultured in 6-well plates at a density of 2×10⁵ cells/well and used for RNA and protein extraction.

2.5 In vitro osteogenic assay and calcium nodule staining

Osteoblasts were seeded in 6-well plates at a density of 2×10⁵ cells per well. After osteogenic induction for 7 days, cells were stained with the ALP staining kit (A59022, Beyotime, Shanghai, China) after fixation with 4% paraformaldehyde for 30 min, and ALP activity was determined with the OD values at 405 nm on a multifunction microplate scanner. Alizarin red staining was performed for visualization of calcium deposits as previously reported. Briefly, mature osteoblasts with 21-day osteogenic induction were fixed using 75% ethanol, and then alizarin red staining solution (1 mg/mL, pH 5.5) (A5533, Sigma-Aldrich, St. Louis, USA) was added. After washing with distilled water, stained cells were photographed. Subsequently, mineralized nodules were incubated with 10% cetylpyridinium chloride, and absorbance at 562 nm was recorded to examine calcium content.

2.6 Assessment of free calcium in BMMs cytoplasm

For the detection of free calcium in the cytoplasm, BMMs were cultured in 96-well plates at a density of 5×10³ cells per well. Live cells at different stages of osteoclast differentiation were incubated with CellProbe Fluo-4 AM (S1060, Beyotime, Shanghai, China) for 30 min, and the fluorescence intensity was detected by a microplate reader at an excitation wavelength of 488 nm and an emission wavelength of 516 nm to determine the level of free calcium.

2.7 Quantitative reverse-transcription polymerase chain reaction (qRT-PCR)

Total RNA was isolated using TRIzol reagent (15596026, Thermo Fisher Scientific, MA, USA) following the manufacturer’s instructions. cDNA synthesis was performed with a SuperRT cDNA Synthesis Kit (CW0471, CWbio, Beijing, China) using one microgram of purified RNA. Synthesized cDNA (1 µL) was used for qRT-PCR analysis with Ultra SYBR Mixture with low ROX (CW3008, CWbio, Beijing, China) on a Bio-Rad thermocycler (Bio-Rad, Hercules, USA) PCR system. The relative expression levels of target genes were calculated using the 2^−ΔΔCt method and normalized to the internal control Actb. The PCR primer sequences are listed in Supplemental Table S1, Additional File 1.

2.8 Western blot analysis

Cells were harvested and lysed on ice in RIPA Lysis Buffer (Sigma, USA). Coomassie brilliant blue R-250 (Bio-Rad, California, USA) staining solution was employed to measure the protein concentration. Equal amounts (30 µg) of protein from each sample were separated on a 10% sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE) and transferred onto polyvinylidene difluoride (PVDF) membranes using a Bio-Rad Trans-Blot SD. Membranes were blocked with 5% nonfat milk and incubated overnight with primary antibodies at 4°C. Then, horseradish peroxidase (HRP)-conjugated secondary antibody at a dilution of 1:5000 was used for 1 hour. The blots were developed with an enhanced chemiluminescent reagent (P10060, NCM Biotech, Suzhou, China) and quantified with a ChemiDoc Touch Imaging System (Bio-Rad, California, USA). Gapdh or Actb was detected as the housekeeping protein. All primary antibodies used are listed in Supplemental Table S2, Additional File 1..

2.9 Statistical analysis

All experiment were performed in triplicate. Statistical analyses were performed using unpaired, two-tailed Student’s t test for comparisons between two groups and one-way ANOVA for comparisons of more than two groups using GraphPad Prism 8.0.2 software (GraphPad Software, La Jolla, CA, USA). The results are presented as the mean ± standard deviation (SD). For all experiments, a P value < 0.05 was considered to indicate a statistically significant difference.

3.1 Activation of Akt reversed Ano5^KI/KI osteoclast differentiation

To further confirm the association of Akt signaling pathway with inhibition of osteoclast differentiation caused by the Ano5^Cys360Tyr mutation, the specific Akt activator SC79 was used to treat BMMs from Ano5^KI/KI mice. Taken into account the evidence that clinical penetrance between female and male patients with GDD did not show different, wild type and Ano5^KI/KI BMMs were cultured from male mice to avoid disturbance of hormone fluctuation. The suppression of Akt phosphorylation was obviously reversed in response to SC79, especially in 15 and 30 min after RANKL induction (Fig. 1a). Importantly, compared with Ano5^KI/KI group, the number of TRAP-positive multinucleated osteoclasts with SC79 treatment became more and even up to be comparable with wild-type group, along with sizable enlargement of the spread area in Ano5^KI/KI BMMs cultures (Fig. 1b-c). These results indicated that Akt activation could facilitate Ano5^Cys360Tyr osteoclast differentiation and maturation.

3.2 Akt activator promoted actin ring formation in Ano5^KI/KI osteoclasts

An intact filamentous actin (F-actin) ring structure is a vital process by which differentiated osteoclasts activate bone resorption by attaching to the bone surface and forming a sealing zone [21]. F-actin is composed of a double-helical polymer of monomeric actin (G-actin) in a globular configuration through burning up energy, and phalloidin can specifically bind to F-actin [22]. Phalloidin staining was performed to explore the reverse effect of the Akt activator on osteoclast differentiation and bone resorption. SC79 supplementation into mutant BMMs cultures completely rescued actin ring formation and made their size enlarge to Ano5^+/+ osteoclasts approximately (Fig. 2a-b). Consistently, the Akt activator induced the expression of dendritic cell-specific transmembrane protein (Dc-stamp) in Ano5^KI/KI BMMs, which is essential for cell-cell fusion and actin ring formation in osteoclasts (Fig. 2c) [23]. There is no significant difference at day 3, SC79 stimulation also enhanced the transcription level of the vacuolar (H⁺) ATPase (v-ATPase) V0 domain (Atp6v0d2) at other stages of osteoclast differentiation (Fig. 2c). Interestingly, it has been reported that Atp6v0d2-deficient mice exhibited representative disruption of osteoclasts fusion similar to Dc-stamp knockout mice. In addition, Atp6v0d2 triggers proton transport to the resorptive lacunae and thus preserves the acidic environment needed for bone degradation [24, 25].

3.3 SC79 positively regulated the expression of osteoclastogenesis-related factors in Ano5^KI/KI BMMs cultures

Following the formation of an actin ring-rich sealing zone and the presence of a ruffled membrane, bone matrix degradation is induced by osteoclast-specific genes [26]. As shown in Fig. 3a, the decreased expression of Trap, cathepsin K (Ctsk), and matrix metalloproteinase-9 (Mmp9) in Ano5^KI/KI BMMs cultures was switched back by SC79 at various differential stages. Furthermore, these factors have multiple sites recognized by Nfatc1, which is known as a significant regulator of osteoclastogenesis, and the reduction in Nfatc1 was also reversed by SC79 stimulation (Fig. 3b). Notably, the level of cytosolic calcium taking part in robust Nfatc1 activation was obviously decreased, which was also rescued due to SC79 intervention (Fig. 3c). In brief, these results suggested the negative effects of the p.Cys360Tyr mutation on osteoclast differentiation and function could be rectified by Akt activation.

3.4 SC79 inhibited osteogenic differentiation and mineralization mediated by the p.Cys360Tyr mutation in Ano5

Bone metabolism relies on the delicate balance between bone resorption mediated by osteoclasts and bone formation mediated by osteoblasts. In light of decreased Akt phosphorylation in Ano5^KI/KI osteoclasts, we further examined the effects of Akt signaling pathway on the alterations in Ano5^KI/KI osteoblast differentiation and mineralization caused by the p.Cys360Tyr mutation. Western blot analysis revealed that the level of Akt phosphorylation was comparable between wild-type and Ano5^KI/KI osteoblasts at day 0 (Fig. 4a). However, Akt phosphorylation was significantly suppressed in Ano5^KI/KI mature osteoblasts after 14 days of osteogenic induction, and this effect was rescued by 5 µg/ml SC79 (Fig. 4b-c). To investigate the intrinsic role of Akt activation on GDD-related enhanced osteogenesis, ALP and alizarin red staining assays were carried out. SC79 stimulation in Ano5^KI/KI osteoblasts diminished excessive ALP activity, which is an early marker of osteogenic differentiation (Fig. 4d). Furthermore, extracellular matrix mineralization, the most vital phenomenon in the late stage of bone formation, was detected by alizarin red staining accompanied by the measurement of calcium content, which showed that many fewer mineralized nodules and calcium deposition were formed after Ano5^KI/KI cells were cultured with the Akt activator SC79 (Fig. 4e).

3.5 Akt activation negatively regulated the expression of osteogenic-related factors in Ano5^KI/KI mCOBs

Subsequently, the influences of the Akt activator on transcription levels of bone-forming related factors in different stages of Ano5^KI/KI mCOB cultures were explored. We found that up-regulation of Runx2, a key regulator of osteoblast differentiation, was reversed almost to the level in Ano5^+/+ group by SC79 in both undifferentiated and mature Ano5^KI/KI mCOB (Fig. 5). Osteopontin (OPN), an important noncollagen protein in bone tissue, is synthesized by osteogenic progenitor cells and bone cells[27], and the upregulated OPN expression was also inhibited by the Akt activator (Fig. 5). Additionally, osteocalcin (Ocn) and collagen type I alpha 1 (Col1a1), which are classical markers of late osteogenic factors and matrix maturation, showed similar trends (Fig. 5). Overall, SC79 partially attenuated the enhanced osteogenesis caused by the GDD-related Ano5 mutation.

In the present study, the Akt activator SC79 promoted the maturation of multinucleated osteoclasts and the formation of intact actin rings in Ano5^KI/KI BMMs cultures, suggesting that Akt activation could effectively protect Ano5^KI/KI osteoclast function. Furthermore, we observed that abnormally enhanced capacity of osteoblast differentiation and matrix mineralization in Ano5^KI/KI mCOB cultures were reversed by an Akt activator, which indicated that Akt signaling is closely associated with aberrant bone remodeling in GDD.

Autosomal dominant mutations in ANO5 are responsible for GDD, which is mainly characterized by enlargement of the mandible, osteomyelitis of the jaws, and cortical thickening of limb bones. In a previous study, we successfully established an Ano5^Cys360Tyr knockin mouse model expressing the human mutation p.Cys360Tyr in Ano5, which significantly exhibited typical traits of patients with GDD. Furthermore, Ano5^KI/KI mCOB displayed enhanced osteoblastogenesis consistent with our previous study in vitro and in another Ano5 knockout mouse model [19, 20, 28]. The phenotype of impaired osteoclast differentiation and bone resorption in Ano5^KI/KI mice is highly correlated with the other Ano5 knockout mice reported by the X, Li group. However, it is currently unclear how ANO5 dominant mutations lead to the bone disorder of GDD.

Increasing evidence in recent years has indicated that ANO5 is closely associated with osteoclast differentiation and maturation. Consistent with the fact that Ano5 overexpression regulates osteoclast maturation through Akt signaling [7], our previous research indicated that the p.Cys360Tyr mutation in Ano5 significantly inhibited Akt activation. To further determine the association between Akt signaling and abnormal osteoclastogenesis in GDD, SC79 was utilized and rescued the inhibition of TRAP⁻positive multinucleated osteoclast formation in Ano5^KI/KI BMMs cultures. The transcription level of Trap was also increased with SC79 stimulation. Importantly, enhanced expression of Nftac1, a vital transcription factor for osteoclastogenesis, was also observed after Akt activation. The classic NFATc1 activation pathway requires an elevation of the intracellular calcium concentration, which then activates calcium/calmodulin-dependent protein phosphatase calcineurin and in turn leads to robust nuclear translocation of NFATC1 [29]. Furthermore, a recent study highlighted that Ano5 deletion in mice significantly diminished calcium oscillations in osteoclasts, which resulted in reduced RANKL-NFATc1 signaling [8]. Similarly, we found that the free calcium levels in the cytoplasm of Ano5^KI/KI osteoclasts were lower than those of wild-type osteoclasts and were surprisingly upregulated by SC79 stimulation, which may be attributed to reciprocal feedback between Akt activation and calcium signaling. Our functional evidence further indicated that inhibited osteoclasts differentiation in GDD is closely related with diminished calcium/Nfatc1 cascade pathway that is regulated by inactive Akt signaling.

In the process of osteoclastic bone absorption, multinucleated osteoclasts undergo rearrangements of the actin cytoskeleton to constitute intact actin rings to form a sealed compartment between the bone surface and basal membrane [26]. Our in vitro data revealed the inhibitory effects of the p.Cys360Tyr mutation on F-actin formation was rescued by Akt activation as well, which was validated by upregulation of Atp6v0d2 and Dc-stamp. Furthermore, the expression of Mmp9 and Ctsk, responsible for the degradation of bone matrix, was enhanced after SC79 stimulation. These results underscored that inhibition of Akt signaling is a crucial molecule in the abnormal osteoclastogenesis of GDD.

Bone homeostasis also relies on osteoblasts mediating bone formation, and Akt signaling plays a critical role in cell viability, inhibiting apoptosis, and cell differentiation [15]. Consistent with the change in osteoclasts, the phosphorylation level of Akt was decreased in mature osteoblasts from Ano5^KI/KI mice. Meanwhile, our results suggested that SC79 inhibited the ALP activity and mineralized nodules formation of Ano5^KI/KI osteoblasts, implying that it is crucial for both the early and late stages of osteogenesis. Furthermore, Akt activation obviously suppressed the expression of Runx2, a crucial regulator for the proliferation of osteoblast progenitors and their differentiation into osteoblasts and involved in inducing the transcription of Ocn and Col1a1, which closely take part in the process of bone matrix formation [30].

Canonical AKT signaling is involved in promoting osteoblast proliferation and differentiation through mTOR and Gsk3β/β-catenin cascades [31]. Nevertheless, the levels of Gsk3β and downstream β-catenin were comparable between Ano5^KI/KI and Ano5^+/+ mCOBs in our study (Fig. S1, Additional File 1), which indicates that the decrease in Akt phosphorylation regulated osteogenesis by means other than interference of the Gsk3β/β-catenin pathway. Several studies have yielded similar findings to ours and showed that inhibition of Akt phosphorylation with imatinib stimulates osteogenesis in MSCs, but the reason is not well understood [32]. Surprisingly, Akt/mTOR signaling could inhibit the autophagy process that is required to maintain osteoblast differentiation and bone matrix secretion. Studies have pointed out that intracellular components of crystal-like structures in the cytoplasm are mainly located in autophagosome-like vesicles, and more convincingly, the apatite crystal components in the vesicles have been identified [33, 34]. We hypothesized that increased osteogenesis caused by the mutation may be due to the reinforcement of autophagic activity. However, our in vitro data showed that the p.Cys360Tyr mutation in Ano5 had no relevant effect on the protein level of LC3II, one of the widely used markers for autophagy, which was further confirmed by comparable levels of Atg5, Atg7, Atg12, and Beclin-1 (Fig. S2, Additional File 1). The enhanced osteoblastogenesis in Ano5^KI/KI mCOBs is independent of autophagy and Gsk3β signaling, while specific factors mechanically contributing to excessive osteoblast differentiation and bone matrix secretion mediated by reduced Akt phosphorylation in the GDD disorder model need to be further explored.

Our present study reveals that Akt activation modulates abnormal bone remodeling in the GDD model by stimulating osteoclast differentiation and inhibiting osteoblast function. Although the detailed mechanism has not been fully elucidated and further research is needed to verify our findings in vivo, this study not only provides a deeper understanding of the pathogenesis of GDD but also lays a new theoretical foundation for targeted molecular therapy.

Ethics approval and consent to participate
All methods were carried out in accordance with relevant guidelines and regulations. This study is reported in accordance with the ARRIVE guidelines. Overall animal experimental designs and protocals were approved by Institutional Animal Care and Use Committee of the Beijing Stomatological Hospital (approval number: KQYY-202012-005).

Consent for publication
Not applicable.

Competing interests
The authors declare no competing interests

Funding

This study was funded by the National Natural Science Foundation of China (Grant #82071103, Grant#81570958) and Young Scientist Program of Beijing Stomatological Hospital, Capital Medical University, YSP202317.

Author Contribution

Y.H. and H.L. were responsible for the conception and design of the work; H.L., S.W., Z.T., and C.M. contributed data collection; Y.H., H.L., S.Z., and R.D. performed formal analysis; Y.H. and H.L. drafted and revised the manuscript. All authors approved the final version of manuscript.

Acknowledgement

We gratefully acknowledge all individuals for participating in this study and for institutional support from the Beijing Stomatological Hospital, Capital Medical University.

Data Availability

The dataset supporting the conclusions of this article is available at our institution contacting the corresponding author.

Riminucci M, Collins MT, Corsi A, Boyde A, Murphey MD, Wientroub S, Kuznetsov SA, Cherman N, Robey PG, Bianco P. Gnathodiaphyseal dysplasia: a syndrome of fibro-osseous lesions of jawbones, bone fragility, and long bone bowing. J Bone Min Res. 2001;16(9):1710–8.
Tsutsumi S, Kamata N, Maruoka Y, Ando M, Tezuka O, Enomoto S, Omura K, Nagayama M, Kudo E, Moritani M, et al. Autosomal dominant gnathodiaphyseal dysplasia maps to chromosome 11p14.3-15.1. J Bone Min Res. 2003;18(3):413–8.
Tsutsumi S, Inoue H, Sakamoto Y, Mizuta K, Kamata N, Itakura M. Molecular cloning and characterization of the murine gnathodiaphyseal dysplasia gene GDD1. Biochem Biophys Res Commun. 2005;331(4):1099–106.
Penttila S, Palmio J, Suominen T, Raheem O, Evila A, Muelas Gomez N, Tasca G, Waddell LB, Clarke NF, Barboi A, et al. Eight new mutations and the expanding phenotype variability in muscular dystrophy caused by ANO5. Neurology. 2012;78(12):897–903.
Pedemonte N, Galietta LJ. Structure and function of TMEM16 proteins (anoctamins). Physiol Rev. 2014;94(2):419–59.
Tran TT, Tobiume K, Hirono C, Fujimoto S, Mizuta K, Kubozono K, Inoue H, Itakura M, Sugita M, Kamata N. TMEM16E (GDD1) exhibits protein instability and distinct characteristics in chloride channel/pore forming ability. J Cell Physiol. 2014;229(2):181–90.
Kim JH, Kim K, Kim I, Seong S, Kim SW, Kim N. Role of anoctamin 5, a gene associated with gnathodiaphyseal dysplasia, in osteoblast and osteoclast differentiation. Bone. 2019;120:432–8.
Li X, Wang L, Wang H, Qin A, Qin X. Ano5 modulates calcium signaling during bone homeostasis in gnathodiaphyseal dysplasia. NPJ Genom Med. 2022;7(1):48.
Sandal S, Arora V, Verma IC. ANO5-associated Gnathodiaphyseal dysplasia with calvarial doughnut lesions: First report in an Asian Indian with an expanded phenotype. Congenit Anom (Kyoto). 2021;61(1):25–6.
Otaify GA, Whyte MP, Gottesman GS, McAlister WH, Eric Gordon J, Hollander A, Andrews MV, El-Mofty SK, Chen WS, Veis DV, et al. Gnathodiaphyseal dysplasia: Severe atypical presentation with novel heterozygous mutation of the anoctamin gene (ANO5). Bone. 2018;107:161–71.
Rolvien T, Koehne T, Kornak U, Lehmann W, Amling M, Schinke T, Oheim R. A Novel ANO5 Mutation Causing Gnathodiaphyseal Dysplasia With High Bone Turnover Osteosclerosis. J Bone Min Res. 2017;32(2):277–84.
Hawkins PT, Jackson TR, Stephens LR. Platelet-derived growth factor stimulates synthesis of PtdIns(3,4,5)P3 by activating a PtdIns(4,5)P2 3-OH kinase. Nature. 1992;358(6382):157–9.
Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996;15(23):6541–51.
Manning BD, Toker A. AKT/PKB Signaling: Navigating the Network. Cell. 2017;169(3):381–405.
Mukherjee A, Rotwein P. Akt promotes BMP2-mediated osteoblast differentiation and bone development. J Cell Sci. 2009;122(Pt 5):716–26.
Suzuki E, Ochiai-Shino H, Aoki H, Onodera S, Saito A, Saito A, Azuma T. Akt activation is required for TGF-beta1-induced osteoblast differentiation of MC3T3-E1 pre-osteoblasts. PLoS ONE. 2014;9(12):e112566.
Kawamura N, Kugimiya F, Oshima Y, Ohba S, Ikeda T, Saito T, Shinoda Y, Kawasaki Y, Ogata N, Hoshi K, et al. Akt1 in osteoblasts and osteoclasts controls bone remodeling. PLoS ONE. 2007;2(10):e1058.
Moon JB, Kim JH, Kim K, Youn BU, Ko A, Lee SY, Kim N. Akt induces osteoclast differentiation through regulating the GSK3beta/NFATc1 signaling cascade. J Immunol. 2012;188(1):163–9.
Li H, Wang X, Chen E, Liu X, Ma X, Miao C, Tian Z, Dong R, Hu Y. Introduction of a Cys360Tyr Mutation in ANO5 Creates a Mouse Model for Gnathodiaphyseal Dysplasia. J Bone Min Res. 2022;37(3):515–30.
Wang X, Liu X, Dong R, Liang C, Reichenberger EJ, Hu Y. Genetic Disruption of Anoctamin 5 in Mice Replicates Human Gnathodiaphyseal Dysplasia (GDD). Calcif Tissue Int. 2019;104(6):679–89.
Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289(5484):1504–8.
Akisaka T, Yoshida H, Inoue S, Shimizu K. Organization of cytoskeletal F-actin, G-actin, and gelsolin in the adhesion structures in cultured osteoclast. J Bone Min Res. 2001;16(7):1248–55.
Yagi M, Miyamoto T, Sawatani Y, Iwamoto K, Hosogane N, Fujita N, Morita K, Ninomiya K, Suzuki T, Miyamoto K, et al. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med. 2005;202(3):345–51.
Kim K, Lee SH, Ha Kim J, Choi Y, Kim N. NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol Endocrinol. 2008;22(1):176–85.
Kim T, Ha HI, Kim N, Yi O, Lee SH, Choi Y. Adrm1 interacts with Atp6v0d2 and regulates osteoclast differentiation. Biochem Biophys Res Commun. 2009;390(3):585–90.
Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423(6937):337–42.
Si J, Wang C, Zhang D, Wang B, Zhou Y. Osteopontin in Bone Metabolism and Bone Diseases. Med Sci Monit. 2020;26:e919159.
Jin L, Liu Y, Sun F, Collins MT, Blackwell K, Woo AS, Reichenberger EJ, Hu Y. Three novel ANO5 missense mutations in Caucasian and Chinese families and sporadic cases with gnathodiaphyseal dysplasia. Sci Rep. 2017;7:40935.
Kang JY, Kang N, Yang YM, Hong JH, Shin DM. The Role of Ca(2+)-NFATc1 Signaling and Its Modulation on Osteoclastogenesis. Int J Mol Sci 2020; 21(10).
Komori T. Regulation of Proliferation, Differentiation and Functions of Osteoblasts by Runx2. Int J Mol Sci 2019; 20(7).
Bai Y, Zhang Q, Chen Q, Zhou Q, Zhang Y, Shi Z, Nong H, Liu M, Zeng G, Zong S. Conditional knockout of the PDK-1 gene in osteoblasts affects osteoblast differentiation and bone formation. J Cell Physiol. 2021;236(7):5432–45.
Fitter S, Dewar AL, Kostakis P, To LB, Hughes TP, Roberts MM, Lynch K, Vernon-Roberts B, Zannettino AC. Long-term imatinib therapy promotes bone formation in CML patients. Blood. 2008;111(5):2538–47.
Nollet M, Santucci-Darmanin S, Breuil V, Al-Sahlanee R, Cros C, Topi M, Momier D, Samson M, Pagnotta S, Cailleteau L, et al. Autophagy in osteoblasts is involved in mineralization and bone homeostasis. Autophagy. 2014;10(11):1965–77.
Guo YF, Su T, Yang M, Li CJ, Guo Q, Xiao Y, Huang Y, Liu Y, Luo XH. The role of autophagy in bone homeostasis. J Cell Physiol. 2021;236(6):4152–73.

No competing interests reported.

Download PDF

Editorial decision: Revision requested
19 Aug, 2024
Editor assigned by journal
13 Aug, 2024
Submission checks completed at journal
13 Aug, 2024
First submitted to journal
11 Aug, 2024

You are reading this latest preprint version

Ano5 Mutation Leads to Bone Dysfunction of Gnathodiaphyseal Dysplasia via Disturbing Akt Signaling

Status:

Version 1

Abstract

Background

Methods

Results

Conclusion

Figures

1. Introduction

2. Methods

2.1 Generation of Ano5^KI/KI mice

2.2 Isolation and culture of mouse osteoclasts

2.3 In vitro osteoclastogenesis assay

2.4 Preparation of mouse calvarial osteoblasts (mCOBs) culture

2.5 In vitro osteogenic assay and calcium nodule staining

2.6 Assessment of free calcium in BMMs cytoplasm

2.7 Quantitative reverse-transcription polymerase chain reaction (qRT-PCR)

2.8 Western blot analysis

2.9 Statistical analysis

3. Results

3.1 Activation of Akt reversed Ano5^KI/KI osteoclast differentiation

3.2 Akt activator promoted actin ring formation in Ano5^KI/KI osteoclasts

3.3 SC79 positively regulated the expression of osteoclastogenesis-related factors in Ano5^KI/KI BMMs cultures

3.4 SC79 inhibited osteogenic differentiation and mineralization mediated by the p.Cys360Tyr mutation in Ano5

3.5 Akt activation negatively regulated the expression of osteogenic-related factors in Ano5^KI/KI mCOBs

4. Discussion

5. Conclusion

Declarations

Consent for publication
Not applicable.

Competing interests
The authors declare no competing interests

Funding

Author Contribution

Acknowledgement

Data Availability

References

Additional Declarations

Supplementary Files

Status:

Version 1

Ano5 Mutation Leads to Bone Dysfunction of Gnathodiaphyseal Dysplasia via Disturbing Akt Signaling

Status:

Version 1

Abstract

Background

Methods

Results

Conclusion

Figures

1. Introduction

2. Methods

2.1 Generation of Ano5KI/KI mice

2.2 Isolation and culture of mouse osteoclasts

2.3 In vitro osteoclastogenesis assay

2.4 Preparation of mouse calvarial osteoblasts (mCOBs) culture

2.5 In vitro osteogenic assay and calcium nodule staining

2.6 Assessment of free calcium in BMMs cytoplasm

2.7 Quantitative reverse-transcription polymerase chain reaction (qRT-PCR)

2.8 Western blot analysis

2.9 Statistical analysis

3. Results

3.1 Activation of Akt reversed Ano5KI/KI osteoclast differentiation

3.2 Akt activator promoted actin ring formation in Ano5KI/KI osteoclasts

3.3 SC79 positively regulated the expression of osteoclastogenesis-related factors in Ano5KI/KI BMMs cultures

3.4 SC79 inhibited osteogenic differentiation and mineralization mediated by the p.Cys360Tyr mutation in Ano5

3.5 Akt activation negatively regulated the expression of osteogenic-related factors in Ano5KI/KI mCOBs

4. Discussion

5. Conclusion

Declarations

Consent for publication Not applicable.

Competing interests The authors declare no competing interests

Funding

Author Contribution

Acknowledgement

Data Availability

References

Additional Declarations

Supplementary Files

Status:

Version 1

2.1 Generation of Ano5^KI/KI mice

3.1 Activation of Akt reversed Ano5^KI/KI osteoclast differentiation

3.2 Akt activator promoted actin ring formation in Ano5^KI/KI osteoclasts

3.3 SC79 positively regulated the expression of osteoclastogenesis-related factors in Ano5^KI/KI BMMs cultures

3.5 Akt activation negatively regulated the expression of osteogenic-related factors in Ano5^KI/KI mCOBs

Consent for publication
Not applicable.

Competing interests
The authors declare no competing interests